Funded companies

Revier Therapeutics

Advancing disease-modifying therapies for patients with cardiometabolic disease

🇪🇺 Heidelberg · Biotechnology

Develops disease-modifying therapies for patients with cardiometabolic disease

Website LinkedIn0 following

SEED · 2mo ago

$6.5M

Total tracked

$6.5M

Open roles

0

How to stand out for Revier Therapeutics

Talent Graph

Apply with your Role Readiness, not just a resume.

Role Readiness is a 0-100 score for your target role, built only from proof - certifications, cleared simulations, ranked projects. It shows a recruiter what you can actually do, in one link, before any interview.

Verified certifications Cleared simulations Ranked projects & GitHub
Sign in & start my Readiness Program

About Revier Therapeutics

Revier has established the first therapeutic approach to selectively target class IIa HDACs to treat cardiometabolic diseases. Our orally available small molecules are designed to inhibit the pathogenic enzymatic activity while preserving healthy biological function and avoiding canonical HDAC inhibition. We are advancing a pipeline of novel disease modulators starting with heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD) as our initial indications.

Our goal is to define a new class of treatments that directly improve cardiometabolic health and provide life-saving, long-term benefits for patients with related diseases.

Open roles

0 listed · tech, AI & data

No open tech roles right now.

We're still locating their careers page.

Talent snapshot

Employee functions

Business Development3
Education2
Healthcare Services1
Media and Communication1
Research1

Employee locations

Utrecht, Netherlands1
Baden-Württemberg, Germany1
Massachusetts, United States1
Germany1
Netherlands1
United States1

Common skills

Cell BiologyBiotechnologyPharmaceuticsTranslational MedicineMolecular BiologyGPCRsOncologyResearch SkillsBiochemistryCardiovascular DiseaseTeam LeadershipmiRNA